Shares of MAP Pharmaceuticals (NASDAQ: MAPP) skyrocketed today, up nearly 60% on the news that the company was being acquired by its marketing partner Allergan (NYSE: AGN) for the premium of $25 per share. In this video, Motley Fool health-care analyst David Williamson tells us some of the unexpected synergies that Allergan, the company behind Botox, will be looking for in MAP Pharmaceuticals, and why this might be a good fit.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
MAP Pharmaceuticals' meteoric rise today.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
MannKind
MNKD
$3.77
(-1.05%)
$0.04
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.